A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Orismilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms IASOS
- Sponsors UNION Therapeutics
- 22 Nov 2023 Results published in the Union Therapeutics Media Release
- 09 Nov 2023 Results assessing efficacy and safety of orismilast in adults with moderate-to-severe plaque psoriasis published in the Journal of the American Academy of Dermatology.
- 06 Oct 2023 According to an Union Therapeutics media release, data from this study will be presented European Academy of Dermatology and Venerology (EADV) Congress 2023 on October 11-14, 2023, in Berlin, Germany.